Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.

Laura FiondaElena RossiniAntonio LaulettaLuca LeonardiLaura TufanoRocco CostanzoPaolo MarchettiMarco SalvettiMatteo GaribaldiStefania MorinoGiovanni Antonini

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)

Eculizumab potentially offers a mechanism-based treatment of MG in patients under anti-programmed cell death protein 1 (PD-1) agents, without interfering with their mechanism of action and avoiding their discontinuation. Larger case series deserve to be evaluated.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
chronic obstructive pulmonary disease
prognostic factors
peritoneal dialysis
protein protein
small molecule
patient reported